NASDAQ:INGN • US45780L1044
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INOGEN INC (INGN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-06-16 | B. Riley Securities | Initiate | Buy |
| 2025-05-22 | Needham | Upgrade | Hold -> Buy |
| 2025-05-08 | Stifel | Maintains | Hold -> Hold |
| 2025-04-09 | Needham | Reiterate | Hold -> Hold |
| 2025-02-27 | Needham | Reiterate | Hold -> Hold |
| 2025-02-26 | Needham | Reiterate | Hold -> Hold |
| 2025-01-30 | Needham | Reiterate | Hold -> Hold |
| 2025-01-14 | Needham | Reiterate | Hold -> Hold |
| 2024-11-08 | Needham | Reiterate | Hold |
| 2024-08-07 | Needham | Reiterate | Hold |
| 2024-05-08 | Needham | Reiterate | Hold |
| 2024-05-08 | Stifel | Maintains | Hold -> Hold |
| 2024-04-09 | Needham | Reiterate | Hold |
| 2024-02-15 | William Blair | Upgrade | Market Perform -> Outperform |
| 2023-11-08 | JP Morgan | Maintains | Underweight -> Underweight |
| 2023-08-08 | Stifel | Maintains | Hold -> Hold |
| 2023-08-08 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-07-14 | Needham | Downgrade | Buy -> Hold |
| 2023-04-20 | Needham | Reiterate | Buy |
| 2023-02-28 | Needham | Reiterate | Buy |
| 2023-02-24 | Needham | Maintains | Buy |
| 2023-01-17 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-11-03 | JP Morgan | Maintains | Neutral |
| 2022-11-02 | Needham | Maintains | Buy |
| 2022-05-09 | Stifel | Maintains | Hold |
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 315.66M -16.31% | 335.705M 6.35% | 348.668M 3.86% | 376.28M 7.92% | 405.86M 7.86% | |
| EBITDA YoY % growth | -45.679M -381.34% | -17.728M 61.19% | -9.548M 46.14% | 6.885M 172.11% | 9.792M 42.22% | |
| EBIT YoY % growth | -63.831M -93.43% | -38.732M 39.32% | -30.207M 22.01% | -24.939M 17.44% | -22.95M 7.98% | |
| Operating Margin | -20.22% | -11.54% | -8.66% | -6.63% | -5.65% | |
| EPS YoY % growth | -2.99 -115.11% | -1.52 49.16% | -0.79 48.03% | -0.86 -8.65% | -0.59 31.49% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.29 -15.46% | -0.16 -5.40% | -0.13 -2.00% | -0.22 15.65% | -0.20 30.04% | -0.11 30.32% | -0.11 17.69% | -0.22 1.86% |
| Revenue Q2Q % growth | 83.997M 2.09% | 99.195M 7.50% | 104.14M 12.72% | 100.37M 22.82% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 408K 116.54% | 2.346M -45.14% | 3.468M -66.30% | 1.632M -85.62% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -9.384M -22.57% | -5.814M 5.14% | -4.08M 23.48% | -5.916M 36.43% | N/A | N/A | N/A | N/A |
All data in USD
8 analysts have analysed INGN and the average price target is 13.26 USD. This implies a price increase of 109.48% is expected in the next year compared to the current price of 6.33.
INOGEN INC (INGN) will report earnings on 2026-05-05, after the market close.
The consensus EPS estimate for the next earnings of INOGEN INC (INGN) is -0.29 USD and the consensus revenue estimate is 84.00M USD.
The consensus rating for INOGEN INC (INGN) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.